News

circle_logo2

CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia

Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone …

CalciMedica Appoints Robert N. Wilson as Co-Chairman of the Board of Directors and Eric W. Roberts as Vice Chairman

Robert N. Wilson was Former Johnson & Johnson Vice Chairman Board Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and …

CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone  LA …

CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences

Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™   LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” …

CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

Scroll to Top